We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Protein Panels Identify Prostate Cancer and Differentiate between Tumors

By LabMedica International staff writers
Posted on 12 Jul 2016
A noninvasive diagnostic test for prostate cancer is based on protein signatures that can differentiate patients from healthy individuals and those with aggressive tumors from those with less dangerous growths.

Investigators at the Ontario Institute for Cancer Research (Toronto, Canada) and their colleagues at the University Health Network (Toronto, Canada) and the Eastern Virginia Medical School (Norfolk, VA, USA) used advanced proteomics techniques to generate expression information for 624 proteins obtained in urine samples. More...
Computational analyses reduced this number by identifying significantly differentially expressed proteins and finally characterized a set of six protein biomarkers for diagnosis and a set of seven protein biomarkers for prognosis of prostate cancer.

"The amazing thing about these signatures is that their rate of accuracy is as good or better than the invasive tests that are used today, with far fewer drawbacks," said contributing author Dr. Paul Boutros, a principal investigator at the Ontario Institute for Cancer Research. "They can replace invasive, expensive, uncomfortable tests with something much easier and simpler. This type of cheap, non-invasive testing could allow patients to be screened much more frequently, allowing for more accurate monitoring of patients' non-aggressive cancer over time, sparing patients biopsies, imaging tests and even unnecessary surgeries."

The test was described in detail in a paper published in the June 28, 2016, online edition of the journal Nature Communications.

Related Links:
Ontario Institute for Cancer Research
University Health Network
Eastern Virginia Medical School

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
ESR Analyzer
iSED PRO
New
Rubella Virus Test
RUB IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.